1. Indications and Usage
\nPulmonary Arterial Hypertension (PAH):
\nTreatment of PAH (WHO Group 1) to reduce symptoms associated with exercise.
\nTarget Population: Patients with NYHA Class II\u2013IV symptoms due to idiopathic or heritable PAH, or PAH associated with connective tissue diseases or congenital systemic-to-pulmonary shunts.
\n2. Dosage and Administration
\nRoute of Administration:
\nContinuous Subcutaneous (SC) or Intravenous (IV) infusion ONLY.
\nRecommended Dosage:
\nInitial Dose: 1.25 ng\/kg\/min. (Reduce to 0.625 ng\/kg\/min if the patient cannot tolerate the initial dose).
\nTitration: Increase by 1.25 ng\/kg\/min weekly for the first 4 weeks, then by 2.5 ng\/kg\/min weekly thereafter, based on clinical response and tolerability.
\nCritical Administration Instructions:
\nContinuous Infusion: Must be administered continuously via an external infusion pump.
\nInterruption: Abrupt cessation or significant reduction in dose can lead to rebound PAH symptoms.
\nIV Preparation: If administered intravenously, must be diluted with Sterile Water for Injection or 0.9% Sodium Chloride.
\nBackup: Patients must have a backup pump and supplies available at all times.
\n3. Mechanism of Action
\nProstacyclin Mimicry:
\nTreprostinil is a stable analog of prostacyclin (PGI2), which is produced endogenously by endothelial cells.
\nReceptor Activation:
\nIt binds to and activates prostacyclin receptors on vascular smooth muscle and platelet cells.
\nTherapeutic Result: This leads to vasodilation (relaxation of smooth muscle in pulmonary and systemic arteries) and inhibition of platelet aggregation, thereby reducing pulmonary vascular resistance and improving exercise capacity.
\n4. Safety and Warnings
\nRebound Hypertension:
\nAbrupt withdrawal or rapid dose reduction may cause rebound pulmonary hypertension symptoms (dyspnea, dizziness, asthenia).
\nBleeding Risk:
\nTreprostinil inhibits platelet aggregation and may increase the risk of bleeding, especially in patients taking anticoagulants.
\nInfusion Site Complications:
\nSC: Pain and erythema are very common. Severe reactions may require conversion to IV.
\nIV: Risk of sepsis and thrombotic events at the catheter site.
\nHypotension:
\nAs a vasodilator, it may cause systemic hypotension, dizziness, or syncope.
\n5.Adverse Reactions and Clinical Research
\nMost Common Adverse Reactions:
\nInjection Site Pain\/Reaction: Extremely common (up to 85% in SC studies).
\nSystemic: Headache, diarrhea, nausea, rash, jaw pain, and flushing.
\nClinical Research Highlights:
\nEfficacy: In a pivotal 12-week placebo-controlled trial, Treprostinil improved the 6-minute walk distance by a mean of 16 meters compared to placebo.
\nDose Correlation: Improvement in exercise capacity was noted to be dose-related.
\n6.Drug Interactions
\nAnticoagulants\/Antiplatelets:
\nUse with caution due to additive bleeding risks (e.g., Warfarin, Heparin).
\nAntihypertensives:
\nAdditive hypotensive effects may occur.
\nCYP450 Enzymes:
\nNo clinically significant interaction with CYP3A4 substrates. (Note: Primarily metabolized by CYP2C8 in some contexts, but no major dose adjustments are typically required for standard inhibitors).
\n7.Pharmaceutical Information
\nChemical Composition:
\nActive Ingredient: Treprostinil (Dimesylate).
\nAppearance: Clear, colorless to slightly yellow solution.
\nPackaging: Single-use vials (various concentrations).
\nStorage: Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F).<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name:\u82ae\u65cb\u96e8 \u00ae\uff08Ruixuan Yu\u00ae\uff09
\nGeneric Name: Treprostinil
\nStrength: 20 mL : 20 mg per vial, 1 vial per box
\nManufacturer: Zhaoke Pharmaceutical Co., Ltd.
\nMarketing Authorization Holder: Zhaoke Pharmaceutical Co., Ltd.
\nApproval Date in China: Domestic generic approval date: 2024
\nRegistration Number: \u56fd\u836f\u51c6\u5b57H20243128
\nStorage: Store refrigerated at 2\u00b0C\u20138\u00b0C, protect from light, do not freeze. After dilution, store at room temperature and use within the specified time frame. Refer to the package insert for full storage requirements.<\/p>\n
Price&Cost:Contact Us now for the best price of Treprostinil\uff08Ruixuan Yu\uff09<\/p>\n","protected":false},"featured_media":4283,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[25,73],"product_tag":[],"class_list":["post-4282","product","type-product","status-publish","has-post-thumbnail","product_cat-injection","product_cat-chinese-innovative-drug","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n